Pharmaceutical companies are sounding the alarm to the European Commission, warning of a potential investment exodus to the United States if proposed tariffs are implemented. This stark message, backed by a survey of 18 major international firms, suggests that 85% of their capital expenditure and 50% of their R&D budgets—estimated at $112.9 billion—are at risk…

Continue Reading